Role of Insulin Resistance in the Alzheimer's Disease Progression.
Role of Insulin Resistance in the Alzheimer's Disease Progression. Neurochem Res. 2020 Apr 20;: Authors: Nguyen TT, Ta QTH, Nguyen TTD, Le TT, Vo VG Abstract Recent studies continue to find evidence linking Type 2 diabetes (T2D) with Alzheimer's disease (AD), the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Insulin resistance or dysfunction of insulin signaling is a universal feature of T2D, the main culprit for altered glucose metabolism and its interdependence on cell death pathways, forming the basis of linking T2D with AD as it may exacerbate Aβ accumulation, tau hyperphosphorylation and devastates glucose transportation, energy metabolism, hippocampal framework and promulgate inflammatory pathways. The current work demonstrates the basic mechanisms of the insulin resistance mediates dysregulation of bioenergetics and progress to AD as a mechanistic link between diabetes mellitus and AD. This work also aimed to provide a potential and feasible zone to succeed in the development of therapies in AD by enhanced hypometabolism and altered insulin signaling. PMID: 32314178 [PubMed - as supplied by publisher]
CONCLUSIONS: Food industry sponsorship of foundations and scientific societies is very widespread in Spain, except among public health associations. Unlike sponsored associations, those unsponsored propose policies opposed by the food industry, which are aimed at improving the system and food and eating environments. PMID: 32660803 [PubMed - as supplied by publisher]
CONCLUSIONS: Aberrant DNA methylation patterns of the FPR1/2/3 gene promoters contribute to disease severity and diabetes mellitus or cardiovascular disease in OSA patients, probably through regulating FPR1/2/3 gene expressions. PMID: 32655788 [PubMed]
Authors: Calderone D, Capodanno D, Angiolillo DJ Abstract INTRODUCTION: - Ticagrelor is an antiplatelet agent acting through direct and reversible competitive inhibition of the platelet P2Y12 receptor. While the clinical merits of ticagrelor in patients who experienced an acute coronary syndrome are widely accepted, its role in stable coronary artery disease is less established. Recently, large-scale trials of ticagrelor have been published in this setting, including a trial in patients with diabetes mellitus (DM). AREAS COVERED: - This review aims to inform about recent findings on ticagrelor, by appraising th...
CONCLUSIONS: Our study is the first study to investigate the association between Ala1369Ser ABCC8 genetic variation and T2DM in the Kurdish population of western Iran. The obtained results clearly show that Ala1369Ser polymorphism of ABCC8 is associated with an increased risk of T2DM in this population. PMID: 32660410 [PubMed - as supplied by publisher]
Authors: Olsen I, Singhrao SK PMID: 32663042 [PubMed - as supplied by publisher]
Discussion and conclusion: The active components that act as hypoglycaemic agents in R. amabilis are procyanidins, which protected MIN6 cells against PA-induced apoptosis by activating PI3K/Akt/FoxO1 signalling. These results indicate that β-cell extraction, combined with UPLC/MS, is a valid method for screening antidiabetic components from herbal medicines. PMID: 32659127 [PubMed - in process]
Maria knew something was wrong. A working mom in her mid-thirties, Maria has diabetes — and she was feeling more fatigued than usual. She thought it could be a urinary tract infection (UTI), so she booked a video visit — a virtual consultation with a physician. The doctor agreed something wasn’t right and sent her off for coordinated and expedited lab work. Those tests showed a UTI wasn’t the problem. Maria’s diabetes had been uncontrolled — and worsening rapidly. The doctor set…
CONCLUSION: Herpetic keratouveitis can be seen as a rare complication of intravitreal ranibizumab injection. To our best knowledge, this is the first case with herpes keratouveitis developed following intravitreal ranibizumab injection. PMID: 32657646 [PubMed - as supplied by publisher]
Publication date: Available online 15 July 2020Source: Science &SportsAuthor(s): O. Abdel-Fattah, K. Atiyat, R. Alshammary
This article reviews key drugs that have been discontinued while in development for AD and delineates the future landscape for present and alternative approaches. EXPERT OPINION: Anti-Aβ drugs have failed to validate the Aβ cascade hypothesis of AD. Early findings suggest that the same is happening with therapeutics targeting tau and focussing future research solely on anti-tau drugs is inappropriate. Alternative targets should be pursued, including apolipoprotein E, immunomodulation, plasma exchange, protein autophagy and clearance, mitochondrial dysfunction, abnormal glucose metabolism, neurovascular unit s...